Researchers at Eli Lilly and Company, AstraZeneca, Novartis, and Pfizer recently highlighted the critical role of solubility measurement in drug discovery and development, addressing the current gap at the discovery-development interface.
“Solubility is a key physicochemical property for the success of any drug candidate” but “an artificial boundary can exist at the discovery-development interface”.
The Solubility Company is proud to have our SPA™ technology mentioned as an innovative technology addressing this gap, especially in terms of solid-state relevant solubility measurement.
Contact Us for more information on how your drug development projects can benefit from access to more relevant data!
Check out the full article here:
Link to Paper
